Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393417 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase 2 study, sponsored by Nielsen BioSciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT02393417 is a Phase 2 study that has completed, run by Nielsen BioSciences. The registered enrollment target is 243 participants.
The verdict
NCT02393417, a Phase 2 study, has completed, sponsored by Nielsen BioSciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
This is a placebo-controlled, double-blind (subject, Investigator, and site staff with the exception of unblinded dedicated staff to handle study medication), phase 2a study with 3 dose cohorts, randomized (concealed) to CANDIN or placebo (3:1). Main study will be up to 20 weeks (10 doses administered every other week) or until a subject has complete resolution of all injectable common warts. Subjects who cannot tolerate dosing every 2 weeks due to a local tolerance issue may be injected at 3-week intervals for up to 10 doses, increasing the length of the study to 29 weeks. Subjects will be followed for 4 months after final injection(s) for evidence of new or reoccurring warts and for safety evaluation.
Interventions
- OTHER Placebo
- BIOLOGICAL CANDIN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393417
The ClinicalTrials.gov registry entry for NCT02393417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nielsen BioSciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02393417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02393417 about?
NCT02393417 is a clinical study titled "Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)". This is a placebo-controlled, double-blind (subject, Investigator, and site staff with the exception of unblinded dedicated staff to handle study medication), phase 2a study with 3 dose cohorts, randomized (concealed) to CANDIN or placebo (3:1). Main study will be up to 20 weeks (10 doses administer...
What is the current status of trial NCT02393417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2015-03. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02393417?
The interventions under investigation include: Placebo (OTHER), CANDIN (BIOLOGICAL).
Who is sponsoring clinical trial NCT02393417?
This trial is sponsored by Nielsen BioSciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.